Login
Israel-Hamas Conflict
Memorial Day
Harvard
Baseball
Education
NCAA
Social Media
Artificial Intelligence
Donald Trump
Soccer
European Union
Senate
Natural Disasters
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

NICE Recommends First Subcutaneous Option for Haemophilia B

Summary by Medscape
The recommendation of marstacimab (Hympavzi) for severe haemophilia B offers the first subcutaneous treatment and potential relief for over 200 eligible patients in England. Medscape News UK

1 Articles

All
Left
Center
Right
MedscapeMedscape

NICE Recommends First Subcutaneous Option for Haemophilia B

The recommendation of marstacimab (Hympavzi) for severe haemophilia B offers the first subcutaneous treatment and potential relief for over 200 eligible patients in England. Medscape News UK

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medscape broke the news in United States on Friday, May 23, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Medical

Medical

England

England

News
For You
SearchBlindspotLocal